Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Inks Comarketing Pacts With Ultivue, ImaBiotech

NEW YORK – Fluidigm on Thursday said it has entered into a pair of comarketing agreements related to its Imaging Mass Cytometry technology platform.

Under a comarketing agreement with Ultivue, the companies will collaborate to offer a comprehensive portfolio of solutions for biomarker discovery and drug development. Cambridge, Massachusetts-based Ultivue uses its InSituPlex technology to develop assays for use in multiplex immunofluorescence imaging and analysis.

Fluidigm's IMC technology, meanwhile, is designed for highly multiplexed, targeted interrogation of tissue sections for 40 or more protein markers per scan. Combining the two platforms provides researchers with an end-to-end service for clinical and translational research, the companies said.

Fluidigm also inked a collaboration and comarketing agreement with ImaBiotech, a contract research organization that offers spatial multiomics services to pharmaceutical researchers with an emphasis on precision medicine approaches to evaluating drug efficacy and toxicity.

ImaBiotech will use Fluidigm's Hyperion Imaging System to offer mass cytometry as one of its core technologies out of its GLP research facilities in the US and Europe.

"Our customers expressed a need for high-multiplex imaging, and that compelled us to acquire a Hyperion Imaging System to meet market needs," ImaBiotech CEO Jonathan Stauber said in a statement. "We are excited for the opportunity to collaborate with Fluidigm in this regard, innovating applications and products, including new panel development, to make Imaging Mass Cytometry an even more powerful tool."

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.